Anales de la RANM

245 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 DESABASTECIMIENTO DE BCG PARA INSTILACIÓN ENDOVESICAL Pérez-Aizpurua X, et al. An RANM. 2021;138(03): 237 - 245 Los pacientes sometidos a un esquema con restric- ción de dosis de BCG intravesical en el contexto de una situación de desabastecimiento a nivel global, presentaron un menor tiempo de supervivencia libre de recidiva y recurrencia tumoral comparados con aquellos sometidos a un esquema completo de tratamiento. La estrategia de reducción de dosis es una opción de riesgo en situaciones de desabastecimiento de BCG para instilación endovesical en el tratamiento de tumores vesicales de alto riesgo no músculo- infiltrantes. 1. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 788-795. 2. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladdertumors.J Urol. 1976; 116(2): 180-183. doi: 10.1016/s0022-5347(17)58737-6. PMID: 820877 3. Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current un- derstanding and the prospect. Biomed Phar- macother. 2020; 129: 110393. doi: 10.1016/j. biopha.2020.110393. 4. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance Bacillus Calmette-Guérin immu- notherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163(4): 1124-1129. 5. Oddens J, Brausi M, Sylvester R et al. Final re- sults of an EORTC-GU cancers group rando- mized study of maintenance Bacillus Calmet- te- Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year ver- sus 3 years of maintenance. EurUrol. 2013; 63: 462-472. 6. Martínez-Pineiro L, Portillo JA, Fernández JM et al. Maintenance therapy with 3-monthly Bacillus Calmette-Guérin for 3 years is not superior to standard induction therapy in high-risk non- muscle- invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol. 2015; 68: 256-262. 7. Grimm MO, van der Heijden AG, Colombel M et al.; EAU Research Foundation NIMBUS Stu- dy Group.Treatment of high-grade non-muscle- invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation Randomised Phase III Cli- nical Trial «NIMBUS». Eur Urol. 2020; 78(5): 690-698. doi: 10.1016/j.eururo.2020.04.066. 8. Babjuk M, Burger M, Comperat EM et al. Euro- pean Association of Urology guidelines on non- muscle-invasive bladder cancer (TaT1 and car- cinoma in situ)—2019 Update. Eur Urol. 2019; 76: 639-657. 9. Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA. Therapeutic options in high-risk non-mus- cle-invasive bladder cancer during the current worldwide shortage of Bacille Calmette-Guérin. Eur Urol. 2015; 67(3): 359-360. doi: 10.1016/j. eururo.2014.11.031.Epub 2014 Nov 28. 10. Alhogbani MM, Picard JA, Fassi-Fehri MH, Ba- det JL, Colombel CM. Prognostic impact of Ba- cillus Calmette-Guérin interruption at the time of induction and consolidation. Urol Ann. 2017; 9(4): 215-320 doi: 10.4103/UA.UA_115_17. 11. Chou R, Selph S, Buckley DI et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta- analysis. J Urology. 2017; 197(5): 1189-1199. 12. Tabayoyong WB, Kamat AM, O’Donnell MA et al. Systematic review on the utilization of main- tenance intravesical chemotherapy in the mana- gement of non–muscle-invasive bladder cancer. Eur Urol Focus. 2018; 4(4): 512-521. 13. Witjes JA, Bruins HM, Cathomas R et al. Eu- ropean Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2020 Guidelines. Eur Urol. 2021; 79(1): 82-104. doi: 10.1016/j.eururo.2020.03.055. 14. Bandari J, Maganty A, MacLeod LC, Davies BJ. manufacturing and the market: rationalizing the shortage of Bacillus Calmette-Guérin. Eur Urol Focus. 2018; 4(4): 481-484. 15. Chang SS, Boorjian SA, Chou R et al. Diag- nosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol. 2016;196(4):1021-1029. 16. National Comprehensive Cancer Network Cli- nical Practice Guidelines in Oncology: Bladder cancer. V.3.2021, 2021. (www.ncnn.org ) CONCLUSIONES BIBLIOGRAFÍA DECLARACIÓN DE TRANSPARENCIA Los autores/as de este artículo declaran no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. Si desea citar nuestro artículo: Pérez-Aizpurua X, Monzó-Gardiner JI, Maqueda-Arellano J, Buendía- Gonzalez E, Cuello-Sánchez L, Tufet i Jaumot JJ, Alonso-Román J, Gómez-Jordana Mañas B,Gonzalez-Enguita C. Consecuencias del desabastecimiento de bcg para instilación endovesical y su efecto sobre la supervivencia libre de recurrencia en tumores vesicales no infiltrantes de alto riesgo. An RANM. 2021;138(03): 237– 245. DOI: 10.32440/ar.2021.138.03. org02